We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

XOMA to Utilize AVEO’s Human Engineering™ Technology

XOMA to Utilize AVEO’s Human Engineering™ Technology

XOMA to Utilize AVEO’s Human Engineering™ Technology

XOMA to Utilize AVEO’s Human Engineering™ Technology

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "XOMA to Utilize AVEO’s Human Engineering™ Technology "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

XOMA Ltd. and AVEO Pharmaceuticals, Inc. have announced an agreement for XOMA to utilize its Human Engineering™ (HE™) technology to humanize AV-299, AVEO's anti-HGF monoclonal antibody.

For work conducted and licenses granted, AVEO will pay XOMA an up-front license fee, development milestones and royalties. AVEO retains all development and commercialization rights to AV-299.

"AV-299 is a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF) which has demonstrated excellent efficacy in preclinical models of human cancer," said Tuan Ha-Ngoc, AVEO's President and CEO.

"Along with AV-412, our AV-299 program is another example of the progress we have made applying our scientific platform to build a portfolio of novel oncology product development programs."

"XOMA's clinically-validated HE™ technology is intended to accelerate product development timelines for the AV-299 program, while increasing the potential for clinical and commercial success."

"The alliance with AVEO represents a new business extension of our HE™ technology, which was previously available only for XOMA's internal and collaborative product development programs," said Jack Castello, XOMA's Chairman, President and CEO.

"We hope this is the first of many HE™ relationships as it joins with our other initiatives to leverage XOMA's innovations, expertise and other assets."

"Importantly, we are pleased to improve the medical and commercial potential of AVEO's AV-299 antibody product candidate through the use of our HE™ technology."